SpyGlass Pharma, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
SGP$36.95+8.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share data)
| As of | ||
|---|---|---|
| March 31, 2026 | December 31, 2025 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $238,902 | $96,358 |
| Short-term investments | 12,100 | 11,078 |
| Other receivables | 653 | 431 |
| Prepaid expenses and other current assets | 1,707 | 901 |
| Total current assets | 253,362 | 108,768 |
| Other non-current assets | 789 | 492 |
| Property and equipment, net | 2,745 | 2,339 |
| Deferred offering costs | — | 2,715 |
| Right-of-use asset | 1,490 | 1,552 |
| Total assets | $258,386 | $115,866 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable | $3,514 | $2,696 |
| Payroll-related accruals | 882 | 2,182 |
| Other current liabilities | 2,271 | 3,706 |
| Total current liabilities | 6,667 | 8,584 |
| Lease liability, non-current | 1,607 | 1,582 |
| Total liabilities | 8,274 | 10,166 |
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible preferred stock, $.00001 par value; 0 shares authorized, issued and outstanding as of March 31, 2026; 116,618,581 shares authorized, 20,341,968 shares issued and outstanding as of December 31, 2025 (aggregate liquidation preference of $0 and $200,878 as of March 31, 2026 and December 31, 2025, respectively) | — | 204,537 |
| Stockholders' equity (deficit) | ||
| Preferred stock, $.00001 par value; 200,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2026; 0 shares authorized, issued, and outstanding as of December 31, 2025 | — | — |
| Common stock, $.00001 par value; 1,000,000,000 shares authorized; 33,432,555 shares issued and outstanding as of March 31, 2026; 154,383,336 shares authorized; 2,203,620 shares issued and outstanding as of December 31, 2025 | — | — |
| Common stock additional paid-in capital | 368,660 | 5,893 |
| Accumulated deficit | (118,548) | (104,730) |
| Total stockholders' equity (deficit) | 250,112 | (98,837) |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $258,386 | $115,866 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.